Scarica l'app Stockscreener
22.47
2.56%
-0.59
Pre-mercato:
22.86
0.39
+1.74%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Nektar Therapeutics Borsa (NKTR) Ultime notizie
Nektar Therapeutics’ Earnings Call Highlights Growth Potential - TipRanks
How Nektar's Rezpegaldesleukin Could Redefine Treatment for Autoimmune Disorders - Dermatology Times
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail
Nektar Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y - MSN
Why Nektar Therapeutics Stock Popped 6% on Friday - MSN
Can Nektar Therapeutics expand into new marketsElite Return Strategy Watch - thegnnews.com
Nektar Therapeutics Q2 2025 Earnings: Revenue Exceeds Estimates, EPS Loss Wider Than Expected, Cash and Investments Down to $175.9 Million - AInvest
Nektar Therapeutics Q2 Earnings: Revenue Down, Net Loss Up, but Cash Position Strong and FDA Fast Track Designation for Rezpegaldesleukin - AInvest
A Quick Look at Today's Ratings for Nektar Therapeutics(NKTR.US), With a Forecast Between $98 to $120 - 富途牛牛
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates - MSN
Nektar Therapeutics 2025 Q2 Earnings Loss Narrows by 21.5% - AInvest
Nektar Therapeutics (NKTR): A High-Risk, High-Reward Biotech Play in the Treg Space - AInvest
Jonathan Zalevsky, PhD, on Rezpegaldesleukin’s Biologic Approach to Alopecia Areata - Dermatology Times
Nektar Therapeutics: Operational Efficiency Gains Amid Revenue Decline—A Path to Profitability or a Temporary Reprieve? - AInvest
Buy Rating for Nektar Therapeutics: Upcoming Catalysts and Strong Financial Performance - TipRanks
Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $105 - 富途牛牛
Transcript : Nektar Therapeutics, Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings call transcript: Nektar Therapeutics reports Q2 2025 earnings miss By Investing.com - Investing.com Australia
Earnings call transcript: Nektar Therapeutics reports Q2 2025 earnings miss - Investing.com
Cautious Hold Rating on Nektar Therapeutics Amid Promising Yet Uncertain Clinical Developments - TipRanks
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Highlights: Str - GuruFocus
Nektar Therapeutics Reports Q2 2025 Financial Results - TipRanks
Nektar (NKTR) Q2 Revenue Falls 52% - The Globe and Mail
Nektar Therapeutics reports results for the quarter ended June 30Earnings Summary - TradingView
Nektar Therapeutics Q2 2025 Earnings: Revenue at $11.2M Beats Es - GuruFocus
Nektar Therapeutics: Strategic Pipeline Progress and Financial Prudence Position for Long-Term Value Creation - AInvest
Nektar Therapeutics (NKTR) Misses Q2 EPS by 258c - StreetInsider
Nektar Reports Game-Changing Atopic Dermatitis Results, Secures FDA Fast Track Status and $115M Funding - Stock Titan
Nektar gets FDA fast track status for alopecia areata drug - MSN
Nektar: Q2 Earnings Snapshot - Norwalk Hour
Nektar Therapeutics Files Amendments To Increase Authorized Common Stock From 300M To 390M Shares And Implement 1-For-15 Reverse Stock Split Effective June 8, 2025; Split-Adjusted Trading To Begin June 9, 2025 - 富途牛牛
Nektar Gears Up to Report Q2 Earnings: What's in the Cards? - MSN
FDA grants fast track designation to Nektar’s rezpegaldesleukin in alopecia areata - PMLiVE
What is the dividend policy of Nektar Therapeutics stockExplosive portfolio gains - Jammu Links News
What drives Nektar Therapeutics stock priceSignificant capital appreciation - Jammu Links News
Should I hold or sell Nektar Therapeutics stock in 2025Achieve consistent profits with proven methods - Jammu Links News
Does Nektar Therapeutics stock perform well during market downturnsAchieve breakthrough growth with proven strategies - Jammu Links News
Nektar Therapeutics (NASDAQ:NKTR) is a favorite amongst institutional investors who own 53% - uk.finance.yahoo.com
What are analysts’ price targets for Nektar Therapeutics in the next 12 monthsStrongest growth potential - Jammu Links News
What institutional investors are buying Nektar Therapeutics stockTrack stocks with high upside potential easily - Jammu Links News
Published on: 2025-08-03 06:56:13 - Jammu Links News
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets - Eastern Progress
Nektar Therapeutics shares rise 4.61% intraday ahead of Q2 financial results announcement. - AInvest
Nektar Therapeutics' Q2 2025 Earnings: A Pivotal Moment for Its Immuno-inflammatory Pipeline and Financial Resilience - AInvest
1.02%
3.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):